SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage ...

Hiring Dalia Rayes as head of commercial for the global efzofitimod franchise slots another piece of the puzzle into place.

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

Tyr Pharma (ATYR) announced the appointment of Dalia Rayes as Head of Commercial, Global Efzofitimod Franchise. She will serve as a member of ...

Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of ...

Xentria's milestone advances XTMAB-16, a potential therapy for this inflammatory disorder with limited treatment options "This marks a significant step forward for the sarcoidosis community ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going ...

Yashoda Hospitals hosts international conference on EBUS for accurate diagnosis of respiratory diseases, benefiting patients ...

Q4 2024 Earnings Call Transcript March 13, 2025 aTyr Pharma, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. Operator: Good afternoon, ladies and gentlemen, and ...